SynthesisTransplantation and cellular therapy2026
Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.
Synthesis in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
In oncology, overall survival (OS) is the benchmark endpoint for assessing therapy effectiveness, but requires large patient cohorts and extended follow-up to attain meaningful data. The identification of reliable surrogate markers for OS may enable earlier treatment decisions and streamline clinical trial design, potentially reducing costs and accelerating access to new therapies. The objective of this study was to evaluate whether complete response (CR) could serve as an early surrogate for OS in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). This study used two data sources: a systematic literature review (SLR) with meta-analyses and patient-level real-world data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry evaluating the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel). Systematic searches of PubMed and EMBASE were conducted to identify clinical trials and real-world cohort studies published between January 2000 and July 2024 that reported CR rates and 1- and 2-yr OS rates in patients who received systemic treatment for r/r LBCL. Meta-analyses were stratified by treatment type, study type, median lines of prior therapy, response criteria, and high-risk status. The CIBMTR study included adult patients with r/r LBCL treated with axi-cel between October 2017 and August 2020 and collected data on CR rate, time to CR (TtCR), and OS. Multivariable analyses adjusted for key prognostic factors were conducted to identify baseline patient characteristics associated with TtCR and OS at Day 100 and Month 6 after axi-cel infusion and to determine the association between OS and CR at Day 100 and Month 6. In the SLR/meta-analysis, a total of 82 original articles were identified through PubMed and EMBASE searches and secondary references. CR rates across treatment modalities were strongly predictive of achieving OS at 1 and 2 yr after treatment in patients with r/r LBCL who were in high-risk cohorts (R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.